Skip to content
Film Television Auditions – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly’s retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial
October 28, 2026
Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
October 27, 2026
Lilly declares fourth-quarter 2026 dividend
October 26, 2026
New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
October 25, 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
October 24, 2026
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
October 22, 2026
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
October 20, 2026
Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
October 19, 2026
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
October 18, 2026
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
October 15, 2026
1
2
3
…
7
Next Page
→